New research indicates that individuals who stop using blockbuster slimming jabs like semaglutide or tirzepatide may regain lost weight at a significantly accelerated pace than those who halt traditional lifestyle plans.
Published data in a major medical journal shows that while obese people frequently drop a large proportion of their total mass while undergoing treatment, the weight is regained at an average rate of nearly a kilo each month once they quit.
"Individuals purchasing such drugs must be aware of the potential of rapid rebound weight gain when the therapy concludes," warns lead investigator Dr. Susan Jebb.
That rate of regain suggests a reversion to starting weight within about 18 months.
Comparing Therapies
The study, which reviewed dozens of studies involving over 9,000 of participants, compared the effects of these new drugs with other pills.
Scientists emphasize that people who shed pounds through diet and exercise generally have a more gradual creep back—approximately 0.1 kg a month—after stopping.
The Reason for the Quick Rebound
Experts believe the mechanism of the drugs explains the amplified regain.
The injections copy a natural hormone called GLP-1, which moderates appetite.
"Sustained high doses of GLP-1 concentrations far above than normal might result in the body to generate a reduced amount of its endogenous GLP-1, and may also reduce sensitivity to its effects," explained Dr. Adam Collins, a dietetics researcher.
"Discontinuation of this hormone supplement results in appetite is uncontrolled, making overeating a significant risk."
An Ongoing Condition?
The NHS recommend the injections for individuals with weight-linked health risks, accompanied by recommended diet and exercise modifications.
Professionals say that, given the high risk of weight regain, the treatment might need to be long-term.
This view is echoed by drug manufacturers, who state that the findings "emphasize the persistent character of excess weight," akin to managing diseases like hypertension.
User Testimonies
People who have discontinued the jabs report a sudden return of hunger.
"It was like a switch activating and you become extremely hungry," recalled a patient.
This difficulty is exacerbated if individuals have not established sustainable dietary or behavioural modifications during therapy.
Significant Interest
Figures indicate that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with demand remaining high.
- Adoption is higher among women compared to males.
- The middle-aged demographic shows the greatest usage rates.
- A large proportion obtain the medications through private prescriptions rather than the NHS.
Ultimately, clinicians stress that while GLP-1 drugs are potent tools for weight loss, they are not a magic solution and lasting health benefits relies on integrated lifestyle support.
